RA
BDTX icon

Royce & Associates’s Black Diamond Therapeutics BDTX Stock Holding History

Royce & Associates’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,831
Closed -$35.9K – 759
2026
Q1 		$35.9K Buy
+16,831
New +$40K ﹤0.01% 774

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Royce & Associates's BDTX Position: Q2 2026 in Review

Royce & Associates sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 16,831 shares — an estimated $35.9K sold.

Royce & Associates first reported a position in BDTX in Q1 2026 and held it in 1 quarter. The position peaked at $35.9K in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Royce & Associates reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Royce & Associates sold 16,831 Black Diamond Therapeutics shares in Q2 2026, an estimated $35.9K.
  • Royce & Associates first reported a position in Black Diamond Therapeutics in Q1 2026 and held it in 1 quarter.
  • Royce & Associates's Black Diamond Therapeutics position peaked at $35.9K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.